In this study, we retrospectively evaluated the treatment regimen of oxaliplatin plus oral fluoropyrimidine (S-1 or capecitabine or fluorouracil) in the first line, of nab-paclitaxel in the second line, and immune checkpoint inhibitors in the third line in patients with Her-2–negative advanced GC. Here, ERBB2 is linked to gastric cancer.